Biography: Patents

Thomas H Beck is a partner and head of the Sidley New York IP group. He focuses on complex chemical and pharmaceutical litigation matters. Mr Beck recently won a two-week jury trial for Sunovion in a Hatch-Waxman litigation against Mylan concerning the asthma medication Xopenex (levalbuterol), winning lost profits, reasonable royalty and a finding of wilful infringement. He is lead counsel for Noven Pharmaceuticals concerning the Daytrana transdermal patch treatment for ADHD, and he is also lead counsel for ConvaTec in litigation concerning negative pressure wound therapy and devices. He was lead IP counsel for LSI in litigation involving programmable field gate arrays and related circuits. Mr Beck has also been lead counsel in multimillion-dollar mediation and arbitration efforts, including Marvell v Agere which involved 802.11 Wi-fi networks.

Mr Beck was lead or co-lead counsel for Eli Lilly, Schering-Plough, GlaxoSmithKline, Bristol-Myers Squibb, Sanofi-Aventis and others concerning, for example, the ADHD drug atomoxetine, the anticholesterol drug ezetimibe, the antidiabetic drug rosiglitazone maleate, the anti-cancer drug paclitaxel and the platelet inhibitor agent clopidogrel bisulfate. He was lead counsel for Bristol in the Bristol v RPR case, in which RPR's patent claims were found unenforceable, and the SDNY awarded Bristol's attorney fees for the six-year battle. He was also lead counsel for defendant Immunomedics concerning labelled antibodies and for plaintiff Enzo Biochem concerning labelled nucleotides.

Mr Beck is a member of the Federal Circuit Bar Association, the AIPLA, the ABA and the NY Intellectual Property Law Association. He received his JD from Harvard Law School in 1979 and his BS in chemistry and mathematics (with honours) from North Dakota State University in 1975. He is admitted to the New York Bar.

Biography: Life Sciences

Thomas H Beck is a partner and head of the Sidley New York IP group. He focuses on complex chemical and pharmaceutical litigation matters. He has also counselled clients regarding drug and biologic candidates, recombinant DNA technologies and medical devices. Mr Beck is lead counsel for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma medication Xopenex (levalbuterol). He is lead counsel for Noven Pharmaceuticals in Hatch-Waxman litigation against Watson concerning the Daytrana transdermal patch treatment for ADHD, and he is also lead counsel for ConvaTec in litigation brought by KCI and Wake Forest University concerning negative pressure wound therapy. He was recently lead IP counsel for LSI in litigation against Xilinx involving numerous patents relating to programmable field gate arrays and related circuits. Mr Beck has also handled several successful multimillion-dollar mediation and arbitration efforts, including a complete win in Marvell v Agere which involved 802.11 Wi-Fi networks.

Mr Beck was lead counsel for Eli Lilly and Company, Bristol-Myers Squibb, and co-lead counsel for Schering-Plough, GlaxoSmithKline, Sanofi Synthelabo and others concerning the ADHD drug atomoxetine, the anti-cholesterol drug ezetimibe, the antidiabetic drub rosiglitazone maleate, the anti-cancer drug paclitaxel and the platelet inhibitor agent clopidogrel bisulfate. He was lead counsel for Bristol in the Bristol v RPR case, in which RPR's patent claims were found unenforceable, and Bristol was awarded its attorney fees for the six-year battle.

Mr Beck has been described as "world class", and "extremely well-versed in patent law with tenacious litigation style ... studious and organized approach" and an ability to "dig very deep into the science" of patent matters. He has been ranked in Chambers USA since 2005, as well as in Best Lawyers and Practical Law Guides among others. He was profiled in the November 2003 IP Law & Business article, "Hooked on Drugs" (pages 36-44) concerning the Bristol v RPR litigation.

Mr Beck is a member of the Federal Circuit Bar Association, the AIPLA, the ABA and the NY Intellectual Property Law Association. He received his JD from Harvard Law School in 1979 and his BS in chemistry and mathematics (with honours) from North Dakota State University in 1975. He is admitted to the New York Bar.